Lipophilic Salts and Lipid Formulations Enable Oral Delivery of Peptide Drug Octreotide
Combining octreotide with lipophilic counter-ions and lipid-based formulations improved oral peptide stability against gut enzymes and enhanced intestinal membrane permeability — advancing oral delivery of this important peptide drug.
Quick Facts
What This Study Found
Lipophilic salt forms of octreotide in lipid-based formulations improved enzymatic stability in GI lumen and intestinal membrane permeability, addressing both major barriers to oral peptide delivery.
Key Numbers
OCT.DoS2 + SEDDS higher absorption; no permeability increase in Caco-2/in situ; reduced enzymatic degradation; prolonged lipid retention
How They Did This
Pharmaceutical formulation study. Lipophilic counter-ion pairing with octreotide. Lipid-based formulation optimization. Enzymatic stability testing. Intestinal permeability assessment.
Why This Research Matters
Octreotide injections are burdensome for patients with chronic conditions. An oral formulation would dramatically improve quality of life and treatment adherence for patients needing long-term octreotide therapy.
The Bigger Picture
The lipophilic salt + lipid formulation strategy is applicable to many peptide drugs beyond octreotide. If proven clinically, this approach could transform oral delivery for the entire peptide drug class.
What This Study Doesn't Tell Us
In vitro formulation study. In vivo oral bioavailability not tested. Lipid-based formulations face stability and manufacturing challenges. Food effects on absorption unknown.
Questions This Raises
- ?Would oral lipophilic octreotide achieve therapeutic plasma levels?
- ?Can this formulation approach be applied to other peptide drugs?
- ?How does food intake affect oral octreotide absorption from lipid formulations?
Trust & Context
- Key Stat:
- Dual barrier solved Lipophilic salt form protects against gut enzymes while lipid carrier enhances membrane crossing — addressing both major oral peptide delivery barriers simultaneously
- Evidence Grade:
- Low evidence grade: in vitro formulation study. Oral bioavailability confirmation needed.
- Study Age:
- Published 2021. Oral octreotide (Mycapssa) was actually approved — validating the oral delivery concept for this peptide.
- Original Title:
- Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide.
- Published In:
- Pharmaceutical research, 38(6), 1125-1137 (2021)
- Authors:
- Li, Peng(4), Ford, Leigh, Haque, Shadabul, McInerney, Mitchell P, Williams, Hywel D, Scammells, Peter J, Thompson, Philip E, Jannin, Vincent, Porter, Christopher J H, Benameur, Hassan, Pouton, Colin W
- Database ID:
- RPEP-05549
Evidence Hierarchy
Frequently Asked Questions
Can octreotide be taken as a pill?
Yes — oral octreotide (Mycapssa) is now FDA-approved. This study contributed to understanding how to make peptide drugs survive the gut and cross the intestinal wall using lipophilic salt forms and lipid-based carriers.
Why is oral peptide delivery so difficult?
Two problems: (1) stomach acid and digestive enzymes destroy peptides, and (2) the intestinal wall blocks large molecules from entering the blood. This study solved both by making octreotide more fat-soluble (lipophilic salt) and wrapping it in a lipid carrier.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05549APA
Li, Peng; Ford, Leigh; Haque, Shadabul; McInerney, Mitchell P; Williams, Hywel D; Scammells, Peter J; Thompson, Philip E; Jannin, Vincent; Porter, Christopher J H; Benameur, Hassan; Pouton, Colin W. (2021). Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide.. Pharmaceutical research, 38(6), 1125-1137. https://doi.org/10.1007/s11095-021-03063-3
MLA
Li, Peng, et al. "Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide.." Pharmaceutical research, 2021. https://doi.org/10.1007/s11095-021-03063-3
RethinkPeptides
RethinkPeptides Research Database. "Lipophilic Salts and Lipid-Based Formulations: Enhancing the..." RPEP-05549. Retrieved from https://rethinkpeptides.com/research/li-2021-lipophilic-salts-and-lipidbased
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.